Goldfarb Branham LLP is investigating whether the board of Genoptix, Inc. (Nasdaq:GXDX) violated shareholder protection laws in connection with the proposed acquisition by Novartis for $25.00 per share. If you are a Genoptix shareholder or have information about this transaction, contact the firm at 877-583-2855 or by email at email@example.com. “This offer represents a 27% premium over Genoptix’s Friday closing price of $19.76,” said securities lawyer Hamilton Lindley. “Analysts have set a high price target $28.00 per share for Genoptix and it traded for $38 per share in May 2010. Also, as part of the deal, management has secured positions for themselves in the going forward company.” Goldfarb Branham’s lawyers have significant experience representing individual and institutional investors in over 100 shareholder class action cases. A firm securities lawyer, Hamilton Lindley, can be reached at firstname.lastname@example.org or 877-583-2855 to discuss the impact of this buyout on Genoptix shareholders.